There are currently 2875 clinical trials in Houston, Texas looking for participants to engage in research studies. Trials are conducted at various facilities, including M D Anderson Cancer Center, University of Texas MD Anderson Cancer Center, Baylor College of Medicine and The University of Texas - MD Anderson Cancer Center. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
A 12-Month Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine
NCT04396574
Recruiting
The reason for this 12-month, open-label study is to see if the study drug lasmiditan is safe and effective for the intermittent acute treatment of migraine in children aged 6 to 17. The study will last about 12 months and may include up to 7 visits.
Gender:
ALL
Ages:
Between 6 years and 17 years
Trial Updated:
07/02/2025
Locations: Pain and Headache Centers of Texas, Houston, Texas
Conditions: Migraine
Register for Updates
CLEANer Aspiration for Pulmonary Embolism
NCT06189313
Recruiting
To evaluate the safety and efficacy of the Cleaner™ Pro Thrombectomy System for aspiration thrombectomy in patients with acute pulmonary embolism (PE).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/02/2025
Locations: Texas Heart Institute, Houston, Texas
Conditions: Pulmonary Embolism, Acute Pulmonary Embolism, Cardiovascular Diseases, Venous Thromboembolism
Register for Updates
A Study to Investigate the Efficacy and Safety of Efgartigimod PH20 SC in Adult Participants With Active Idiopathic Inflammatory Myopathy.
NCT05523167
Recruiting
This study's purpose is to measure the treatment response from efgartigimod PH20 SC compared with placebo in participants with Idiopathic Inflammatory Myopathy (IIM). Participants with the IIM subtypes of dermatomyositis (DM), immune-mediated necrotizing myopathy (IMNM), or certain other subtypes of polymyositis (PM; including antisynthetase syndrome \[ASyS\]) will be included in the study. Treatment response will be measured by Total improvement score (TIS). Additional information can be found... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/02/2025
Locations: McGovern Medical School -The University of Texas Health Science Center at Houston, Houston, Texas +1 locations
Conditions: Active Idiopathic Inflammatory Myopathy, Myositis, Dermatomyositis, Polymyositis, Immune-Mediated Necrotizing Myopathy, Antisynthetase Syndrome
Register for Updates
Study Comparing Tarlatamab and Durvalumab Versus Durvalumab Alone in First-Line Extensive-Stage Small-Cell Lung Cancer (ES-SCLC) Following Platinum, Etoposide and Durvalumab
NCT06211036
Recruiting
The primary objective of this study is to compare the efficacy of tarlatamab plus durvalumab with durvalumab alone on prolonging overall survival (OS).
Gender:
ALL
Ages:
Between 18 years and 99 years
Trial Updated:
07/02/2025
Locations: University of Texas MD Anderson Cancer Center, Houston, Texas
Conditions: Extensive-Stage Small-Cell Lung Cancer, Small-Cell Lung Cancer
Register for Updates
Symptomatic Carotid Outcomes Registry
NCT05300737
Recruiting
The purpose of this study is to build upon trials done over 30 years ago, which did not include statins, new antiplatelet agents, and newer antihypertensive medications. Since the landmark trials (NASCET, ECST), there have been new developments in medical stroke prevention, which creates a gap in knowledge. The aim of this study is to evaluate that clinical care with Intensive Medical Therapy (IMT) alone, the one year stroke rate in patients with symptomatic carotid stenosis and low risk clinica... Read More
Gender:
ALL
Ages:
40 years and above
Trial Updated:
07/02/2025
Locations: Baylor Medicine, Houston, Texas
Conditions: Carotid Stenosis, Ischemic Stroke, Transient Ischemic Attack
Register for Updates
A Study to Evaluate the Safety and Efficacy of Axatilimab in Combination With Ruxolitinib in Participants With Newly Diagnosed Chronic Graft-Versus-Host Disease
NCT06388564
Recruiting
This study will be conducted to determine the preliminary efficacy of axatilimab in combination with ruxolitinib and to assess the contribution of axatilimab to the combination treatment effect in participants with cGVHD.
Gender:
ALL
Ages:
12 years and above
Trial Updated:
07/02/2025
Locations: Md Anderson Cancer Center, Houston, Texas
Conditions: Chronic Graft-versus-host-disease
Register for Updates
A Phase 2, Dose Ranging Study Assessing Rocatinlimab in Moderate-to-severe Asthma
NCT06376045
Recruiting
The primary objective of this study is to describe the efficacy of rocatinlimab in reducing asthma exacerbations.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
07/02/2025
Locations: Baylor College of Medicine, Houston, Texas
Conditions: Asthma
Register for Updates
Targeted Reversal of Inflammation in Pediatric Sepsis-induced MODS
NCT05267821
Recruiting
The TRIPS study is a prospective, multi-center, double-blind, adaptively randomized, placebo-controlled clinical trial of the drug anakinra for reversal of moderate to severe hyperinflammation in children with sepsis-induced multiple organ dysfunction syndrome (MODS).
Gender:
ALL
Ages:
Between 1 day and 17 years
Trial Updated:
07/02/2025
Locations: Texas Children's Hospital, Houston, Texas
Conditions: Pediatric Sepsis-induced Multiple Organ Dysfunction Syndrome (MODS)
Register for Updates
Multicenter Study of Lumateperone for the Treatment of Irritability Associated With Autism Spectrum Disorder in Pediatric Patients
NCT06690398
Recruiting
This is a multicenter, randomized, double-blind, placebo-controlled study in pediatric patients aged 5 to 17 years with a primary diagnosis of irritability associated with Autism Spectrum Disorder (ASD) based on Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition Text Revision (DSM-5-TR) and confirmed by the Kiddie Schedule for Affective Disorders and Schizophrenia Present and Lifetime Version (K-SADS-PL).
Gender:
ALL
Ages:
Between 5 years and 17 years
Trial Updated:
07/02/2025
Locations: Clinical Site, Houston, Texas
Conditions: Irritability Associated With Autism Spectrum Disorder
Register for Updates
Efficacy and Safety of Rexlemestrocel-L Combined With HA* in Participants With Moderate to Severe Chronic Low Back Pain
NCT06325566
Recruiting
The primary purpose of this study is to evaluate the efficacy of rexlemestrocel-L+HA compared to control in reducing low back pain at 12 months post-treatment and safety of a single injection of rexlemestrocel-L+HA injected into a lumbar intervertebral disc compared to control through 12 months post-treatment.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/02/2025
Locations: Paradigm Research Center/Houston Scoliosis and Spine Institute, Houston, Texas
Conditions: Degenerative Disc Disease
Register for Updates
CardiolRx in Recurrent Pericarditis Following IL-1 Blocker Cessation
NCT06708299
Recruiting
Multi-center, randomized, double-blind, placebo-controlled, phase-3 Trial. Patients with a history of recurrent pericarditis who are being treated with an IL-1 blocker for at least 12 months, scheduled to be discontinued, will be approached for potential trial participation. Double-blind treatment will be initiated 10 - 14 days prior to the last scheduled dose of the IL-1 blocker and continued for 24 weeks. The objective is to assess whether patients who discontinue therapy with an IL-1 blocke... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/02/2025
Locations: Houston Methodist Hospital, Houston, Texas
Conditions: Recurrent Pericarditis
Register for Updates
Acceptability & Safety of Two Sequential Doses of Psilocybin in Bipolar Disorder II Depression and Suicidality
NCT06706232
Recruiting
The purpose of the study is to assess the safety and acceptability of up to two sequential administrations of 25 mg psilocybin with additional therapeutic support in decreasing suicidality in patients with Bipolar Disorder (BD II) depression.
Gender:
ALL
Ages:
Between 25 years and 70 years
Trial Updated:
07/02/2025
Locations: The University of Texas Health Science Center at Houston, Houston, Texas
Conditions: Bipolar II Disorder, Depression, Bipolar, Suicidality
Register for Updates